PharmaCyte Biotech PMCB
NASDAQ PMCB
$0.35 +0.01 (+1.86%)
As of: Oct 22, 2026 · 3:59 PM EDT

PharmaCyte Biotech (PMCB) Receivables - Other (2013)

Updated

PharmaCyte Biotech (PMCB) reported Receivables - Other of $1.03 million for fiscal Q4 2013 (quarter ended Apr 30, 2013).

Analysis

PharmaCyte Biotech (PMCB) Receivables - Other (2013) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,165.22 Bn 1,133.81 Bn 19.71 Bn
2 Johnson & Johnson 646.28 Bn 566.14 Bn 17.30 Bn
3 AbbVie 503.17 Bn 476.28 Bn 12.70 Bn
4 Merck 365.23 Bn 319.60 Bn 12.21 Bn
5 Novartis Ag 302.66 Bn 266.65 Bn 11.24 Bn
6 Astrazeneca 267.39 Bn 241.08 Bn 12.86 Bn
7 Amgen 241.61 Bn 197.01 Bn 7.24 Bn
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn
9 Pfizer 172.91 Bn 119.55 Bn 10.94 Bn
10 PharmaCyte Biotech 3.79 Mn -69.05 Mn -
Historic Data

Historic Data

Download Data
DateValue
Apr 30, 2013 1.03 Mn
API Access

PharmaCyte Biotech Receivables - Other API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables-other&ticker=PMCB&period=max&api_key=YOUR_API_KEY